πŸ‡ΊπŸ‡Έ FDA
Patent

US 10676486

Macrocyclic RIP2 kinase inhibitors

granted A61PA61P29/00

Quick answer

US patent 10676486 (Macrocyclic RIP2 kinase inhibitors) held by Oncodesign SA expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Oncodesign SA
Grant date
Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P29/00